Health Care Co. Beats Privacy Patent Suit At Fed. Circ.

Roxane Laboratories Inc. blasted a New Jersey federal judge’s ruling that a generic calcium acetate drug from Hetero Drugs Ltd. units likely doesn’t infringe Roxane kidney medication PhosLo and should therefore be allowed on the market, explaining to a Federal Circuit panel that the difference in capsule size between the two drugs is insignificant in view of the patent claims.

Rate this item
(0 votes)
Login to post comments

Newsletter Subscription

Joomla forms builder by JoomlaShine

IP2017 Banner 380x280

IP Era 300x250

Go to top